On Thursday, RBC Capital maintained its positive stance on Zimmer Biomet Holdings Inc. (NYSE:ZBH), a medical device company, reiterating an Outperform rating and a $140.00 price target. The affirmation followed Zimmer Biomet's investor day, which took place on Wednesday at the New York Stock Exchange, where the company presented its strategic and financial goals for the upcoming years.
During the event, Zimmer Biomet outlined its expectation to achieve revenue growth exceeding its end-markets by more than 100 basis points and to expand its annual operating margin by 30 basis points from 2024 to 2027. Moreover, the company aims for its earnings per share (EPS) to grow at least 1.5 times the average reported revenue growth, with free cash flow (FCF) increasing at least 100 basis points faster than EPS growth.
Zimmer Biomet also emphasized that mergers and acquisitions (M&A) will continue to be a key area of focus. The company indicated it has the financial capacity to invest $5-6 billion in acquisition deals during the long-range plan (LRP) period.
RBC Capital expressed confidence in Zimmer Biomet's LRP targets, considering them to be a conservative estimate with the potential for further growth. The firm's reiteration of the Outperform rating and the $140 stock price target reflects this positive outlook on the company's financial prospects and strategic initiatives.
InvestingPro Insights
In light of RBC Capital's optimistic outlook on Zimmer Biomet (NYSE:ZBH), current metrics from InvestingPro provide additional context for investors. Zimmer Biomet's management's proactive approach to share buybacks is a positive signal of confidence in the company's valuation.
Moreover, despite 20 analysts revising their earnings expectations downwards for the upcoming period, the company's fundamentals exhibit resilience. Zimmer Biomet is trading at a P/E ratio of 24.75, which adjusts to a more attractive 19.74 when considering the last twelve months as of Q1 2024. This lower adjusted P/E ratio may indicate a potential undervaluation relative to near-term earnings growth.
The company's stability is reflected in its low price volatility, and a commitment to shareholder returns is evident with a history of 13 consecutive years of dividend payments. The PEG ratio for the last twelve months as of Q1 2024 stands at 0.21, suggesting that the stock could be undervalued based on its earnings growth. Furthermore, with a solid gross profit margin of 71.88% for the same period, Zimmer Biomet demonstrates operational efficiency.
For investors seeking more detailed analysis, there are additional InvestingPro Tips available, which can be explored for a deeper dive into Zimmer Biomet's financial health and future prospects. To enhance your investment strategy with these insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. Remember, with 6 more InvestingPro Tips available, there's a wealth of information to help guide your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.